Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
Original Article
D. Rischin, S. Porceddu, F. Day, D.P. Brungs, H. Christie, J.E. Jackson, B.N. Stein, Y.B. Su, R. Ladwa, G. Adams, S.E. Bowyer, Z. Otty, N. Yamazaki, P. Bossi, A. Challapalli, A. Hauschild, A.M. Lim, V.A. Patel, J.L. Walker, M.D.L.V. Schurmann, P. Queirolo, J. Cañueto, F.A.F.d. Silva, A. Stratigos, A. Guminski, C. Lin, F. Damian, L. Flatz, A.E. Taylor, D.R. Carr, S. Harris, D. Kirtbaya, G. Quereux, P. Rutkowski, N. Basset-Seguin, N.I. Khushalani, C. Robert, H. Ju, C. Joseph, S. Bansal, C.-I. Chen, F. Seebach, S.-Y. Yoo, I. Lowy, P. Goncalves, and M.G. Fury
N Engl J Med 2025;393:774-785
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.